You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Turning Point Therapeutics on Saturday reported on the activity of TPX-0022 in multiple solid tumor types and said it would discuss with the US Food and Drug Administration the use of the data for registrational purposes.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.
The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.